27.06 02:36 | dpa-AFX: Merck : FDA Issues Complete Response Letter For Patritumab Deruxtecan In EGFR-Mutated NSCLC |
26.06 08:00 | dpa-AFX: Merck : USDA Approves NOBIVAC NXT, First RNA-Particle Vaccine For Canine Flu H3N2 |
18.06 14:19 | dpa-AFX: Ligand Says Merck Receives FDA Approval For CAPVAXIVE For Adults |
18.06 14:05 | dpa-AFX: *LIGAND SAYS MERCK RECEIVES FDA APPROVAL FOR PNEUMOCOCCAL 21-VALENT CONJUGATE VACCINE FOR ADULTS |
03.06 17:10 | dpa-AFX: Merck Says MRNA-4157-Keytruda Combination Data Shows Improvement In High-Risk Melanoma Patients |
03.06 16:05 | dpa-AFX: *MERCK : MRNA-4157-KEYTRUDA COMBINATION DATA SHOWS SUSTAINED BENEFITS IN HIGH-RISK MELANOMA PATIENTS |
03.06 04:32 | dpa-AFX: Immutep Collaborates With Merck To Evaluate Efti In Combination Therapy For Metastatic NSCLC |
01.06 15:53 | dpa-AFX: Lilly Announces Updated Data From Phase 1/2 Study Of Olomorasib In Advanced Solid Tumors |
30.05 11:56 | dpa-AFX: Biotech Stocks Facing FDA Decision In June 2024 |
29.05 12:57 | dpa-AFX: Merck To Acquire EyeBio; Deal Valued Up To $3 Bln |
29.05 12:51 | dpa-AFX: *MERCK SEES EYEBIO DEAL TO RECORD A CHARGE OF ABOUT $1.3 BLN, OR ABOUT $0.50 PER SHARE |
29.05 12:50 | dpa-AFX: *MERCK SEES EYEBIO DEAL TO CLOSE IN Q3 OF 2024 |
29.05 12:49 | dpa-AFX: *MERCK & CO KAUFT FÜR BIS ZU 1,7 MRD USD AUGENFIRMA EYEBIO |
29.05 12:48 | dpa-AFX: *MERCK TO ACQUIRE EYEBIO FOR UP TO $3 BLN |
29.05 12:15 | MARKT USA/Zinsanstieg sorgt für Vorsicht bei Aktien |
29.05 04:09 | dpa-AFX: Merck Nears $1.3 Bln Cash Deal To Buy EyeBio, With Potential $1.7 Bln In Milestone Payments : Report |
28.05 13:14 | dpa-AFX: Merck Reports Positive Phase 3 KEYTRUDA Plus Chemotherapy Trial Results In TNBC Patients |
28.05 12:50 | dpa-AFX: *MERCK SAYS PHASE 3 KEYNOTE-522 TRIAL OF KEYTRUDA IN COMBINATION WITH CHEMOTHERAPY MEETS OVERALL SURVIVAL ENDPOINT |
13.05 13:07 | dpa-AFX: Merck Discontinues Vibostolimab And Pembrolizumab Coformulation Arm Of Phase 3 Trial In Melanoma |
13.05 12:50 | dpa-AFX: *MERCK ANNOUNCES DISCONTINUATION OF VIBOSTOLIMAB AND PEMBROLIZUMAB COFORMULATION ARM OF PHASE 3 KEYVIBE-010 TRIAL |
|